HLA-A (Major Histocompatibility Complex Class I A) is a key gene located on chromosome 6p21.3 within the human leukocyte antigen (HLA) complex. It encodes the alpha chain of the HLA class I molecule, a cell surface glycoprotein essential for immune surveillance and antigen presentation to CD8+ cytotoxic T-lymphocytes[1][2].
HLA class I molecules are expressed on the surface of virtually all nucleated cells and present endogenously synthesized peptide antigens to CD8+ T-cells. This process is fundamental to immune defense against intracellular pathogens ( viruses and some bacteria) and malignant transformation. Beyond this classical function, increasing evidence implicates HLA class I molecules in broader biological processes, including immune regulation in the central nervous system (CNS)[3][4].
The HLA-A gene is extraordinarily polymorphic, with thousands of documented alleles across global populations. This diversity has significant implications for disease susceptibility, transplant matching, and therapeutic response[5].
| Property | Value |
|---|---|
| Gene Symbol | HLA-A |
| Full Name | Major Histocompatibility Complex Class I A |
| Chromosomal Location | 6p21.3 |
| NCBI Gene ID | 3105 |
| Ensembl ID | ENSG00000206503 |
| UniProt ID | P01890 |
| OMIM | 142800 |
The HLA-A gene spans approximately 2.6 kb and comprises 8 exons:
HLA-A encodes a transmembrane glycoprotein consisting of:
The peptide binding groove has pockets (B and F being most important) that determine peptide binding specificity. Different HLA-A alleles have distinct peptide binding preferences.
HLA-A is expressed:
The primary function of HLA-A involves antigen presentation:
HLA-A has additional functions beyond antigen presentation[4:1][6]:
HLA-A alleles have been studied in multiple sclerosis[7]:
| Allele | Association | Effect |
|---|---|---|
| HLA-A*02:01 | Risk allele | Increased susceptibility |
| HLA-A*03:01 | Risk allele | Modest effect |
| HLA-A*24:02 | Protective | In some populations |
The HLA region contributes significantly to MS genetic risk, with HLA-DRB1*15:01 being the strongest individual effect.
HLA-A and the broader HLA class I region have been implicated in Parkinson's disease susceptibility[8][9][10]:
HLA class I molecules have complex roles in Alzheimer's disease[@g ao2020][12]:
The HLA-A gene has thousands of documented alleles:
| Allele | Caucasians | Asians | Africans |
|---|---|---|---|
| A*02:01 | ~30% | ~15% | ~20% |
| A*03:01 | ~20% | ~5% | ~10% |
| A*24:02 | ~10% | ~35% | ~15% |
| A*01:01 | ~15% | ~5% | ~10% |
HLA-A matching is critical for:
HLA-A is relevant for[13]:
Potential therapeutic approaches include:
The brain has specialized immune regulation:
In healthy CNS:
Disease-associated changes include[14]:
HLA-A expression is subject to epigenetic regulation:
Chromatin states affect HLA-A:
microRNAs modulate HLA-A:
HLA-A folding occurs in the endoplasmic reticulum:
ER stress affects HLA-A processing in neurodegeneration.
Autophagy and HLA-A intersect:
The neuroimmune axis involves HLA-A:
HLA-A interacts with multiple receptors:
T-cell Receptor (TCR): Primary interaction
Killer Cell Immunoglobulin-like Receptors (KIRs)
CD8 Co-receptor
HLA-A presents diverse peptides:
Transplantation requires HLA-A matching:
Beyond neurodegeneration:
HLA-A represents a critical intersection between adaptive immunity and neurodegenerative disease. Its role in antigen presentation, immune regulation in the CNS, and genetic associations with disease risk make it an important target for understanding neurodegeneration. Key implications include:
Further research into HLA class I biology will provide insights into neurodegenerative disease mechanisms and potential therapeutic approaches.
The HLA system. N Engl J Med. 2000. ↩︎
HLA complex: from gene to function. Immunogenetics. 2009. ↩︎
HLA class I and immune regulation in the brain. Prog Mol Biol Transl Sci. 2010. ↩︎
HLA class I molecules couple to multiple receptor tyrosine kinases. J Immunol. 2013. ↩︎ ↩︎
The HLA system: genetics and disease association. Transfusion. 2007. ↩︎
The emerging role of HLA class I in neurodegenerative disease. Nat Rev Neurol. 2017. ↩︎
HLA in multiple sclerosis and other autoimmune diseases. Brain. 2002. ↩︎
Microglial HLA-DR and CD4 T cells in Parkinson's disease. Acta Neuropathol. 2018. ↩︎
HLA-DRB1 and Parkinson's disease risk: a meta-analysis. Neurology. 2019. ↩︎
Common genetic variation in HLA region affects PD risk. Brain. 2021. ↩︎
HLA genotype influence on alpha-synuclein aggregation. Ann Neurol. 2019. ↩︎
HLA expression in microglia: implications for neurodegeneration. Glia. 2023. ↩︎
Targeting HLA-class I pathways for neurodegenerative disease therapy. Nat Rev Drug Discov. 2024. ↩︎
HLA class I-mediated neuroprotection in neurodegeneration. Neurobiol Dis. 2022. ↩︎